| DTLGX | VIGIX | DTLGX / VIGIX | |
| Total Expense Ratio | 1.30 | 0.04 | 3,250% |
| Annual Report Gross Expense Ratio | 1.32 | 0.04 | 3,300% |
| Fund Existence | 33 years | 28 years | - |
| Gain YTD | 20.400 | 20.262 | 101% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000 | 5000000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 287M | 357B | 0% |
| Annual Yield % from dividends | 0.00 | 0.41 | - |
| Returns for 1 year | 6.82 | 20.73 | 33% |
| Returns for 3 years | 62.16 | 114.62 | 54% |
| Returns for 5 years | 0.30 | 107.24 | 0% |
| Returns for 10 years | 26.09 | 367.81 | 7% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FBTDX | 150.19 | -1.85 | -1.22% |
| Franklin Biotechnology Discovery C | |||
| HGXYX | 16.61 | -0.25 | -1.48% |
| Hartford Global Impact Y | |||
| TRZLX | 46.20 | -0.70 | -1.49% |
| T. Rowe Price US Large-Cap Core Z | |||
| QAACX | 52.34 | -0.90 | -1.69% |
| Federated Hermes MDT All Cap Core A | |||
| ZVGNX | 57.61 | -2.76 | -4.57% |
| Zevenbergen Genea Investor | |||